Study design (if review, criteria of inclusion for studies)
HTA report
Participants
patients with CF and Pseudomonas aeruginosa
Interventions
Tobramycin inhalation solution
Outcome measures
No studies comparing the differences between both Tobramycin inhalation solution presentations have been found. High quality evidence provided by one single comparative study of the two inhaled formulations did not find significant differences in clinically relevant results. It was found that Tobramycin inhalation powder has advantages in terms of administration and higher satisfaction for the patients although its use is associated to an increased use of other antibiotics and more side effects such as cough. In Argentina, the cost of the treatment implemented in this study is somewhat higher with Tobramycin inhalation powder than with Tobramycin inhalation solution.